Delphi advisor to SelectImmune Pharma AB in connection with its issue of units and listing on Spotlight Stock Market

Delphi has advised SelectImmune Pharma AB (“SelectImmune”) in connection with a unit issue of approximately SEK 30 million, as well as listing on Spotlight Stock Market.

SelectImmune’s shares has been approved for trading on Spotlight Stock Market with first day of trading today, 26 June 2019.

SelectImmune is an innovative biotech company that develops immunotherapy as an alternative to antibiotics. The research that forms the basis of SelectImmune’s business has been conducted for over 20 years at Lund University, which has resulted in five well-documented strategies for combating infection without antibiotics. The company’s business concept is to develop the new drugs for clinical proof-of-concept before they are further developed or licensed to actors in the pharmaceutical industry.

Delphi’s team consisted of Mats Dahlberg, responsible partner, Matilda Karlsson and Clara Jarbrand.